文献速递系统性红斑狼疮其他结缔组织病

Evans综合征预测持续性抗磷脂抗体儿童进展为抗磷脂综合征和/或系统性红斑狼疮

Evans Syndrome Predicts Progression to Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus in Children With Persistent Antiphospholipid Antibodies: A Prospective Cohort Study With Up to 29 Years of Follow-Up.
PubMed 文献 · Arthritis Rheumatol · 2026-07-16

该前瞻性队列研究纳入42例持续性抗磷脂抗体阳性且伴血液学表现的儿童,随访至成年,中位随访长达29年。40例可评估患儿中11例(27.5%)进展为APS和/或SLE。Evans综合征起病者进展风险最高(HR 6.21,95%CI 1.46-26.41),孤立性血小板减少症风险最低。

要点

  • Evans综合征是持续性aPL儿童进展为APS和/或SLE的最强预测因素。
  • 孤立性血小板减少症进展风险最低,病程多呈惰性。
  • AIHA为中间状态,未独立预测进展。

核心结论

  • 在持续性aPL阳性儿童中,Evans综合征是与进展为APS和/或SLE关联最强的血液学表型。
  • 孤立性血小板减少症病程多呈惰性,AIHA未独立预测进展。
  • 动态血液学表型可能改善风险分层并指导长期监测策略。

研究设计与样本

  • 前瞻性队列研究,纳入1995至2024年一家三级儿童风湿病中心收治的42例<18岁持续性aPL阳性伴血液学受累患儿,随访延伸至成年。
  • 主要终点为进展为临床可分类的APS和/或SLE,采用Kaplan-Meier和Cox比例风险模型评估基线及时间依赖性预测因素。

主要发现

  • 40例可评估患儿中11例(27.5%)进展为APS和/或SLE。
  • 与孤立性血小板减少症相比,起病时Evans综合征进展风险最高(HR 6.21,95%CI 1.46-26.41)。
  • 时间依赖性分析中,随访期间新发Evans综合征仍与进展相关。
  • 孤立性血小板减少症风险最低,AIHA为中间状态但未独立预测进展。
  • 狼疮抗凝物几乎普遍存在,进展者中更常见广泛高风险aPL谱但未达统计学显著性。

关键数值与推荐

  • Evans综合征起病者进展HR 6.21(95%CI 1.46-26.41),对照为孤立性血小板减少症。
  • 40例可评估患儿中11例(27.5%)进展为APS和/或SLE。

临床怎么用

  • 对持续性aPL阳性且伴Evans综合征的儿童应加强长期监测,警惕APS和/或SLE进展。
  • 孤立性血小板减少症患儿可采取相对宽松的随访策略。
  • 动态评估血液学表型演变有助于风险分层。

局限性

  • 样本量小(42例入组,40例可评估),单中心三级转诊中心,结果外推需谨慎。
  • 原文未报告多因素校正后的独立预测因素及具体监测间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to characterize the long-term clinical course of children with hematologic noncriteria manifestations and persistent antiphospholipid antibodies (aPLs) and to identify predictors of progression to antiphospholipid syndrome (APS) and/or systemic lupus erythematosus (SLE). METHODS: We conducted a prospective cohort study of children (<18 years old) with persistent aPL positivity and hematologic involvement (thrombocytopenia, autoimmune hemolytic anemia [AIHA], or Evans syndrome) observed at a tertiary pediatric rheumatology center between 1995 and 2024, with follow-up extending into adulthood. Progression to clinically classifiable APS and/or SLE was the primary endpoint. Kaplan-Meier and Cox proportional hazards models evaluated predictors at presentation and in complementary time-dependent analyses. RESULTS: Among 42 enrolled children, 40 were evaluable, of whom 11 (27.5%) progressed to APS and/or SLE. Evans syndrome at presentation was associated with the highest hazard of progression compared with isolated thrombocytopenia (hazard ratio 6.21, 95% confidence interval 1.46-26.41). In time-dependent analyses, Evans syndrome emerging during follow-up remained associated with progression. Isolated thrombocytopenia showed the lowest risk, whereas AIHA represented an intermediate state that did not independently predict progression. Lupus anticoagulant was nearly universal, and broader high-risk aPL profiles were more common among progressors but were not statistically significant. CONCLUSION: In children with persistent aPL positivity, Evans syndrome was the hematologic phenotype most strongly associated with progression to APS and/or SLE, whereas isolated thrombocytopenia followed a largely indolent course. Evolving hematologic phenotypes may improve risk stratification and inform long-term monitoring strategies within the APS-SLE spectrum.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Baca V, Hernández-López D, González-Muñiz S, et al. Evans Syndrome Predicts Progression to Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus in Children With Persistent Antiphospholipid Antibodies: A Prospective Cohort Study With Up to 29 Years of Follow-Up. Arthritis Rheumatol. 2026. PMID: 42463986. doi:10.1002/art.70277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。